Future of automated insulin delivery systems

Diabetes Technology and Therapeutics

Volumn 19, Issue , 2017, Pages S67-S72

  Castle, Jessica R ^a   DeVries, J Hans ^b   Kovatchev, Boris ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Artificial pancreas; Continuous glucose monitoring; Type 1 diabetes

Indexed keywords

GLUCOSE; INSULIN;

ACCURACY; ALGORITHM; ARTICLE; AUTOMATION; BLOOD GLUCOSE MONITORING; DRUG DELIVERY SYSTEM; EXERCISE; GLUCOSE SENSOR; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; DEVICES; INSULIN INFUSION; TRENDS;

BLOOD GLUCOSE SELF-MONITORING; HUMANS; INSULIN INFUSION SYSTEMS;

EID: 85020455289     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2017.0012     Document Type: Article

References (67)

1. Ruan Y, Thabit H, Leelarathna L, et al.: Variability of insulin requirements over 12 weeks of closed-loop insulin delivery in adults with type 1 diabetes. Diabetes Care 2016;39:830-832.
2. Hovorka R: Continuous glucose monitoring and closedloop systems. Diabet Med 2006;23:1-12.
3. Steil GM, Panteleon AE, Rebrin K: Closed-loop insulin delivery-the path to physiological glucose control. Adv Drug Deliv Rev 2004;56:125-144.
4. Cobelli C, Man CD, Sparacino G, et al.: Diabetes: models, signals, and control. IEEE Rev Biomed Eng 2009;2:54-96.
5. Doyle FJ, Huyett LM, Lee JB, et al.: Closed-loop artificial pancreas systems: engineering the algorithms. Diabetes Care 2014;37:1191-1197.
6. Hovorka R: Closed-loop insulin delivery: from bench to clinical practice. Nat Rev Endocrinol 2011;7:385-395.
7. Kropff J, Bruttomesso D, Doll W, et al.: Accuracy of two continuous glucose monitoring systems: a head-to-head comparison under clinical research centre and daily life conditions. Diabetes Obes Metab 2015;17:343-349.
8. Wentholt IM, VollebregtMA, Hart AA, et al.: Comparison of a needle-type and a microdialysis continuous glucose monitor in type 1 diabetic patients. Diabetes Care 2005;28:2871-2876.
9. Fachinetti A, Sparacino G, Guerra S, et al.: Real-time improvement of continuous glucose monitoring accuracy; the smart sensor concept. Diabetes Care 2013;26:793-800.
10. Klueh U, Liu Z, Feldman B, et al.: Metabolic biofouling of glucose sensors in vivo: role of tissue microhemorrhages. J Diabetes Sci Technol 2011;5:583-595.
11. Klueh U, Qiao Y, Czajkowski C, et al.: Basement membranebased glucose sensor coatings enhance continuous glucose monitoring in vivo. J Diabetes Sci Technol 2015;9:957-965.
12. CLSI: Performance metrics for continuous interstitial glucose monitoring; approved guideline. CLSI document POCT05-A. Wayne, PA:Clinical and Laboratory Standards Institute; 2008.
13. Clarke WL: The original Clarke Error Grid Analysis (EGA). Diabetes Technol Ther 2005;7:776-779.
14. Kovatchev BP, Gonder-Frederick LA, Cox DJ, et al.: Evaluating the accuracy of continuous glucose-monitoring sensors: continuous glucose-error grid analysis illustrated by TheraSense Freestyle Navigator data. Diabetes Care 2004;27:1922-1928.
15. Pfutzner A, Klonoff DC, Pardo S, et al.: Technical aspects of the Parkes error grid. J Diabetes Sci Technol 2013;7:1275-1281.
16. Klonoff DC, Lias C, Vigersky R, et al.: The surveillance error grid. J Diabetes Sci Technol 2014;8:658-672.
17. Andelin M, Kropff J, Matuleviciene V, et al.: Assessing the accuracy of continuous glucose monitoring (CGM) calibrated with capillary values using capillary or venous glucose levels as a reference. J Diabetes Sci Technol 2016;10:876-884.
18. Castle JR, Ward WK: Amperometric glucose sensors: sources of error and potential benefit of redundancy. J Diabetes Sci Technol 2010;4:221-225.
19. Bequette BW: Challenges and recent progress in the development of a closed-loop artificial pancreas. Annu Rev Control 2012;36:255-266.
20. Kovatchev BP: Hypoglycemia reduction and accuracy of continuous glucose monitoring. Diabetes Technol Ther 2015;17:530-533.
21. Kovatchev BP, Patek SD, Ortiz EA, et al.: Assessing sensor accuracy for non-adjunct use of continuous glucose monitoring. Diabetes Technol Ther 2015;17:177-186.
22. Leelarathna L, Nodale M, Allen JM, et al.: Evaluating the accuracy and large inaccuracy of two continuous glucose monitoring systems. Diabetes Technol Ther 2013;15:143-149.
23. Maahs DM, Calhoun P, Buckingham BA, et al.: A randomized trial of a home system to reduce nocturnal hypoglycemia in type 1 diabetes. Diabetes Care 2014;37:1885-1891.
24. Buckingham BA, Cameron F, Calhoun P, et al.: Outpatient safety assessment of an in-home predictive low-glucose suspend system with type 1 diabetes subjects at elevated risk of nocturnal hypoglycemia. Diabetes Technol Ther 2013;15:622-627.
25. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-986.
26. Bailey T, Bode BW, ChristiansenMP, et al.: The performance and usability of a factory-calibrated flash glucose monitoring system. Diabetes Technol Ther 2015;17:787-794.
27. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, et al.: Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 2016;388:2254-2263.
28. Kropff J, Choudhary P, Neupane S, et al.: Accuracy and longevity of an implantable continuous glucose sensor in the PRECISE Study: a 180-day, prospective, multicenter, pivotal trial. Diabetes Care 2017;40:63-68.
29. Wang X, Ioacara S, DeHennis A: Long-term home study on nocturnal hypoglycemic alarms using a new fully implantable continuous glucose monitoring system in type 1 diabetes. Diabetes Technol Ther 2015;17:780-786.
30. Cobelli C, Renard E, Kovatchev BP, et al.: Pilot studies of wearable outpatient artificial pancreas in type 1 diabetes. Diabetes Care 2012;35:e65-e67.
31. Kovatchev BP, Renard E, Cobelli C, et al.: Safety of outpatient closed-loop control: first randomized crossover trials of a wearable artificial pancreas. Diabetes Care 2014;37:1789-1796.
32. Anderson SM, Raghinaru D, Pinsker JE, et al.: Multinational home use of closed-loop control is safe and effective. Diabetes Care 2016;39:1143-1150.
33. Kovatchev B, Cheng P, Anderson SM, et al.: Feasibility of long-term closed-loop control: a multicenter 6-month trial of 24/7 automated insulin delivery. Diabetes Technol Ther 2017;19:18-24.
34. Kropff J, Del Favero S, Place J, et al.: 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. Lancet Diabetes Endocrinol 2015;3:939-947.
35. Thabit H, Hovorka R: Coming of age: the artificial pancreas for type 1 diabetes. Diabetologia 2016;59:1795-1805.
36. Nimri R, Muller I, Atlas E, et al.: MD-Logic overnight control for 6 weeks of home use in patients with type 1 diabetes: randomized crossover trial.DiabetesCare 2014;37:3025-3032.
37. Thabit H, Tauschmann M, Allen JM, et al.: Home use of an artificial beta cell in type 1 diabetes. N Engl J Med 2015; 373:2129-2140.
38. Ruiz JL, Sherr JL, Cengiz E, et al.: Effect of insulin feedback on closed-loop glucose control: a crossover study. J Diabetes Sci Technol 2012;6:1123-1130.
39. Bergenstal RM, Garg S, Weinzimer SA, et al.: Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA 2016;316:1407-1408.
40. DeVries JH: The artificial pancreas-ready for prime time? Lancet Diabetes Endocrinol 2017;5:238-239.
41. Dagogo-Jack SE, Craft S, Cryer PE: Hypoglycemiaassociated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest 1993;91:819-828.
42. Castle JR: Is glucagon needed in type 1 diabetes? Lancet Diabetes Endocrinol 2015;3:578-579.
43. Castle JR, Engle JM, El Youssef J, et al.: Novel use of glucagon in a closed-loop systemfor prevention of hypoglycemia in type 1 diabetes. Diabetes Care 2010;33:1282-1287.
44. Russell SJ, El-Khatib FH, Sinha M, et al.: Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med 2014;371:313-325.
45. Haidar A, Legault L, Messier V, et al.: Comparison of dualhormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial. Lancet Diabetes Endocrinol 2015;3:17-26.
46. Blauw H, van Bon AC, Koops R, et al.: Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home. Diabetes Obes Metab 2016;18:671-677.
47. Castle JR, Youssef JE, Branigan D, et al.: Comparative pharmacokinetic/pharmacodynamic study of liquid stable glucagon versus lyophilized glucagon in type 1 diabetes subjects. J Diabetes Sci Technol 2016;10:1101-1107.
48. Hinshaw L, Schiavon M, Mallad A, et al.: Effects of delayed gastric emptying on postprandial glucose kinetics, insulin sensitivity, and beta-cell function. Am J Physiol Endocrinol Metab 2014;307:E494-E502.
49. Woerle HJ, Albrecht M, Linke R, et al.: Importance of changes in gastric emptying for postprandial plasma glucose fluxes in healthy humans. Am J Physiol Endocrinol Metab 2008;294:E103-E109.
50. Weinzimer SA, Sherr JL, Cengiz E, et al.: Effect of pramlintide on prandial glycemic excursions during closedloop control in adolescents and young adults with type 1 diabetes. Diabetes Care 2012;35:1994-1999.
51. Micheletto F, Dalla Man C, Kolterman O, et al.: In silico design of optimal ratio for co-administration of pramlintide and insulin in type 1 diabetes. Diabetes Technol Ther 2013;15:802-809.
52. Riddle MC, Yuen KC, de Bruin TW, et al.: Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes. Diabetes Obes Metab 2015;17:904-907.
53. McMahon SK, Ferreira LD, Ratnam N, et al.: Glucose requirements to maintain euglycemia after moderate-intensity afternoon exercise in adolescents with type 1 diabetes are increased in a biphasic manner. J Clin Endocrinol Metab 2007;92:963-968.
54. Garcia A, Rack-Gomer AL, Bhavaraju NC, et al.: Dexcom G4AP: an advanced continuous glucose monitor for the artificial pancreas. J Diabetes Sci Technol 2013;7:1436-1445.
55. Keenan DB,Mastrototaro JJ, Zisser H, et al.: Accuracy of the Enlite 6-day glucose sensorwith guardian and Veo calibration algorithms. Diabetes Technol Ther 2012;14:225-231.
56. Schiavon M, Dalla Man C, Kudva YC, et al.: In silico optimization of basal insulin infusion rate during exercise: implication for artificial pancreas. J Diabetes Sci Technol 2013;7:1461-1469.
57. Taleb N, Emami A, Suppere C, et al.: Efficacy of singlehormone and dual-hormone artificial pancreas during continuous and interval exercise in adult patients with type 1 diabetes: randomised controlled crossover trial. Diabetologia 2016;59:2561-2571.
58. Breton MD, Brown SA, Karvetski CH, et al.: Adding heart rate signal to a control-to-range artificial pancreas system improves the protection against hypoglycemia during exercise in type 1 diabetes. Diabetes Technol Ther 2014;16:506-511.
59. DeBoer MD, Chernavvsky DR, Topchyan K, et al.: Heart rate informed artificial pancreas system enhances glycemic control during exercise in adolescents with T1D. Pediatr Diabetes 2016.
60. Jacobs PG, Resalat N, El Youssef J, et al.: Incorporating an exercise detection, grading, and hormone dosing algorithm into the artificial pancreas using accelerometry and heart rate. J Diabetes Sci Technol 2015;9:1175-1184.
61. Jacobs PG, El Youssef J, Reddy R, et al.: Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy. Diabetes Obes Metab 2016;18:1110-1119.
62. Heinemann L, Muchmore D: Coverage of prandial insulin requirements: an elusive goal. Diabetes Technol Ther 2017;19:7-8.
63. Diabetes Technology Society: Standard for wireless disbetes device security. May 23, 2016. www.diabetestechnology .org/dtsec-standard-final.pdf (accessed March 28, 2017).
64. Luijf YM, Mader JK, Doll W, et al.: Accuracy and reliability of continuous glucose monitoring systems: a head-to-head comparison. Diabetes Technol Ther 2013;15:722-727.
65. Thabit H, Leelarathna L, Wilinska ME, et al.: Accuracy of continuous glucose monitoring during three closed-loop home studies under free-living conditions. Diabetes Technol Ther 2015;17:801-807.
66. Christiansen M, Bailey T,Watkins E, et al.:A new-generation continuous glucose monitoring system: improved accuracy and reliability compared with a previous-generation system. Diabetes Technol Ther 2013;15:881-888.
67. Peyser TA, Nakamura K, Price D, et al.: Hypoglycemic accuracy and improved low glucose alerts of the latest dexcom G4 platinum continuous glucose monitoring system. Diabetes Technol Ther 2015;17:548-554.